MORRIS PLAINS, N.J., July 19, 2011 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases,today announced the issue of U.S. Patent No. 7,981,398 covering additional claims for the patent family “PEGylation by the Dock and Lock (DNL) technique.”
